<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Prostarm Info Systems Ltd. (PROSTARM) — Tipsheet</title>
    <link>https://tipsheet.markets/company/prostarm/</link>
    <atom:link href="https://tipsheet.markets/company/prostarm/feed.xml" rel="self" type="application/rss+xml" />
    <description>Every Tipsheet Editorial note covering Prostarm Info Systems Ltd. (PROSTARM), newest first. Grounded in BSE/NSE primary-source filings.</description>
    <language>en-in</language>
    <lastBuildDate>Mon, 06 Jul 2026 10:22:48 GMT</lastBuildDate>
    <item>
      <title>Prostarm relocates servo stabilizer, lithium battery units</title>
      <link>https://tipsheet.markets/prostarm-prostarm-relocates-servo-stabilizer-lithium-battery-units-108979/</link>
      <guid isPermaLink="true">https://tipsheet.markets/prostarm-prostarm-relocates-servo-stabilizer-lithium-battery-units-108979/</guid>
      <pubDate>Tue, 16 Jun 2026 17:02:42 GMT</pubDate>
      <description>The micro-cap electric equipment maker moves two operations accounting for about 7.89% of revenue, but gives no cost or capacity figures.</description>
      <content:encoded><![CDATA[<p><em>The micro-cap electric equipment maker moves two operations accounting for about 7.89% of revenue, but gives no cost or capacity figures.</em></p>
<h3>What’s new</h3><ul><li>Prostarm is moving its Servo Stabilizer &amp; Isolation Transformers unit from Pisoli to Mahape.</li><li>Its Lithium Battery vertical is relocating from Mahape to Bakrol, Ahmedabad.</li><li>The company says the moves are for operational efficiency but hasn't quantified savings or capacity impact.</li></ul>
<h3>Why it matters</h3><p>For a ₹835 cr company, internal moves on about 7.89% of revenue are not financially material. The lack of cost/benefit details makes this a routine operational decision rather than a strategic catalyst.</p>
<h3>What we’re watching</h3><ul><li>Whether Prostarm provides any cost-saving or capacity figures in subsequent communications.</li><li>Impact on margins if consolidation yields efficiencies.</li><li>Any further realignments as part of strategic review.</li></ul>
<h3>The full read</h3><p>Prostarm Info Systems is shifting two manufacturing operations: the Servo Stabilizer and Isolation Transformers business (<strong>1.34%</strong> of FY26 turnover) from Pisoli to Mahape, and the Lithium Battery vertical (<strong>6.55%</strong> of turnover) from Mahape to Bakrol, Ahmedabad. Together, they account for <strong>7.89%</strong> of revenue. The company describes the move as consolidation for operational efficiency and resource optimisation. But it hasn't quantified expected cost savings, revenue impact, or changes to production capacity. For a micro-cap with a market cap of <strong>₹835 crore</strong>, this internal realignment looks routine. The lack of financial materiality or surprise means the filing is unlikely to alter the investment case.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=544410&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=PROSTARM">NSE</a></p>]]></content:encoded>
      <category>Other</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
    <item>
      <title>Prostarm cuts margin guidance, delays Jhajjar battery plant</title>
      <link>https://tipsheet.markets/prostarm-prostarm-cuts-margin-guidance-delays-jhajjar-battery-plant-97413/</link>
      <guid isPermaLink="true">https://tipsheet.markets/prostarm-prostarm-cuts-margin-guidance-delays-jhajjar-battery-plant-97413/</guid>
      <pubDate>Mon, 25 May 2026 15:46:25 GMT</pubDate>
      <description>The company narrowed FY27 EBITDA guidance to 12-13% and pushed its flagship energy-storage project into the next fiscal year.</description>
      <content:encoded><![CDATA[<p><em>The company narrowed FY27 EBITDA guidance to 12-13% and pushed its flagship energy-storage project into the next fiscal year.</em></p>
<h3>What’s new</h3><ul><li>EBITDA margin guidance cut to 12-13% from 12-15% citing supply chain disruptions and project mix.</li><li>1.2 GWh Jhajjar battery plant commissioning delayed to end-Q1 FY27 from Q4 FY26.</li><li>First-year capacity utilization expectation lowered to 25-40% from 40-50%.</li></ul>
<h3>Why it matters</h3><p>The margin cut and project delay are a one-two punch. The tighter band signals the 12% floor is now the base expectation, not the midpoint. Delaying Jhajjar pushes Prostarm's energy-storage story deeper into a year where profitability is already shrinking.</p>
<h3>What we’re watching</h3><ul><li>Whether the ₹1,202 cr order book converts into the guided ₹430-450 cr FY27 revenue base.</li><li>Progress on the West Asia-linked ₹68 cr in deferred orders.</li><li>Q1 FY27 receivables and working capital trend after the Q4 spike to ₹254 cr.</li></ul>
<h3>The full read</h3><p>Prostarm Info Systems just tightened its own outlook. It cut FY27 EBITDA margin guidance to <strong>12-13%</strong> from <strong>12-15%</strong>, delayed the <strong>1.2 GWh</strong> Jhajjar battery plant to end-Q1 FY27, and sliced first-year utilization estimates to <strong>25-40%</strong> from <strong>40-50%</strong>. The revenue growth target of at least <strong>25%</strong> on a <strong>₹430-450 crore</strong> base survived, underpinned by a <strong>₹1,202 crore</strong> order book. But Q4 execution revealed fragility. <strong>₹68 crore</strong> in West Asian orders got deferred, and receivables spiked to <strong>₹254 crore</strong>. The Jhajjar delay is the most consequential move. It pushes the company's big bet on battery storage deeper into a fiscal year where margins are already shrinking.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=544410&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=PROSTARM">NSE</a></p>]]></content:encoded>
      <category>Earnings</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
    <item>
      <title>Prostarm reports FY26 standalone profit of ₹34.74 cr</title>
      <link>https://tipsheet.markets/prostarm-prostarm-reports-fy26-standalone-profit-of-34-74-cr-95853/</link>
      <guid isPermaLink="true">https://tipsheet.markets/prostarm-prostarm-reports-fy26-standalone-profit-of-34-74-cr-95853/</guid>
      <pubDate>Fri, 22 May 2026 17:41:23 GMT</pubDate>
      <description>Annual revenue grew 9% to ₹377.88 cr while the board moved to reallocate IPO proceeds.</description>
      <content:encoded><![CDATA[<p><em>Annual revenue grew 9% to ₹377.88 cr while the board moved to reallocate IPO proceeds.</em></p>
<h3>What’s new</h3><ul><li>Standalone revenue reached ₹377.88 cr for FY26.</li><li>Auditors signed off with an unmodified opinion.</li><li>The board proposed changing how the company uses IPO funds, pending shareholder approval.</li></ul>
<h3>Why it matters</h3><p>The company met market expectations without deviation. The pending vote on IPO fund usage is the only factor requiring further action from shareholders.</p>
<h3>What we’re watching</h3><ul><li>Shareholder approval for the modified IPO fund allocation.</li><li>The impact of the fund reallocation on upcoming project timelines.</li><li>Profit margins in Q1 to sustain the 14% annual growth rate.</li></ul>
<h3>The full read</h3><p>Prostarm Info Systems closed FY26 with a 9% rise in revenue to ₹377.88 cr and a 14% increase in standalone profit to ₹34.74 cr. Auditors provided an unmodified opinion on these results. These numbers follow previous market guidance. The board also proposed changes to how it uses proceeds from its IPO. Shareholders must vote on this shift before the company proceeds. This update adds no surprises to the company's financial story. The next test is the shareholder vote on the fund allocation, which will dictate how capital moves through the balance sheet next year.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=544410&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=PROSTARM">NSE</a></p>]]></content:encoded>
      <category>Earnings</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
    <item>
      <title>Prostarm Info Systems reports 14% profit growth for FY26</title>
      <link>https://tipsheet.markets/prostarm-prostarm-info-systems-reports-14-profit-growth-for-fy26-95784/</link>
      <guid isPermaLink="true">https://tipsheet.markets/prostarm-prostarm-info-systems-reports-14-profit-growth-for-fy26-95784/</guid>
      <pubDate>Fri, 22 May 2026 17:23:31 GMT</pubDate>
      <description>Annual results arrive with an unmodified audit opinion, alongside proposals for ESOP amendments and IPO fund reallocation.</description>
      <content:encoded><![CDATA[<p><em>Annual results arrive with an unmodified audit opinion, alongside proposals for ESOP amendments and IPO fund reallocation.</em></p>
<h3>What’s new</h3><ul><li>Standalone revenue climbed 9% to ₹377.88 cr for the full year.</li><li>Auditors provided an unmodified opinion on the annual standalone and consolidated results.</li><li>The board seeks shareholder approval to shift how it uses remaining IPO proceeds.</li></ul>
<h3>Why it matters</h3><p>The results present a steady performance without deviation from market expectations. With the audit opinion clear, the focus for shareholders moves to the pending vote on reallocating IPO funds.</p>
<h3>What we’re watching</h3><ul><li>The timeline for the extraordinary general meeting regarding IPO object variations.</li><li>Any material updates on the new ESOP schemes.</li><li>Quarterly segment margins in the upcoming analyst call.</li></ul>
<h3>The full read</h3><p>Prostarm Info Systems delivered a predictable set of FY26 results, showing standalone revenue growth of 9% to ₹377.88 crore and a 14% lift in profit to ₹34.74 crore. Auditors signed off with an unmodified opinion, reinforcing the routine nature of the disclosure. Beyond the financials, the board is asking shareholders to greenlight changes to how the company uses its IPO proceeds. They also updated their ESOP policy. These items fit the expected corporate housekeeping for a firm of this size. There are no surprises here, and for now, the business remains on its established path. The next test for the board is securing shareholder support for the shift in capital allocation.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=544410&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=PROSTARM">NSE</a></p>]]></content:encoded>
      <category>Earnings</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
  </channel>
</rss>